Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Travoprost
Drug ID BADD_D02265
Description Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure [FDA Label]. It is a synthetic prostaglandin F2alpha analog [FDA Label]. Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypotension [L5155]. Furthermore, this approval also solidifies the medication as the first and only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride [L5155]. Moreover, travoprost is also currently approved in the EU for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146, L5152].
Indications and Usage Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension [F3061, F3064, L5146]. Travoprost is also currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146].
Marketing Status approved
ATC Code S01EE04
DrugBank ID DB00287
KEGG ID D01964
MeSH ID D000069557
PubChem ID 5282226
TTD Drug ID D09CZA
NDC Product Code 82231-114; 54893-0020; 63190-0350; 63629-8840; 61556-040; 64181-0028; 51407-731; 60505-0593; 63629-8839; 24002-0022; 65035-131; 68245-0003; 0781-6185; 40016-006; 0078-0946; 55359-540; 65129-1207
UNII WJ68R08KX9
Synonyms Travoprost | Travatan Z | Z, Travatan | Travatan | (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester | AL-6221 | AL 6221 | AL6221
Chemical Information
Molecular Formula C26H35F3O6
CAS Registry Number 157283-68-6
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Photophobia06.01.01.004; 17.17.02.0060.002057%
Photopsia06.02.06.004; 17.17.01.006--
Prostatic disorder21.04.01.001---
Prostatic specific antigen increased13.23.01.003---
Pruritus23.03.12.001--
Punctate keratitis06.04.02.0030.000404%-
Rash23.03.13.001---
Retinal detachment06.09.03.003; 12.01.04.0040.000276%
Retinal haemorrhage06.10.01.001; 24.07.05.003---
Retinal pigmentation06.09.03.008---
Rhinitis11.01.13.004; 22.07.03.006--
Scab23.03.03.004---
Sinusitis11.01.13.005; 22.07.03.007--
Skin discolouration23.03.03.0050.001029%-
Skin disorder23.03.03.007---
Skin exfoliation23.03.07.0030.000276%-
Skin hyperpigmentation23.05.01.003--
Skin irritation23.03.04.0090.000404%-
Tachycardia02.03.02.007---
Tenderness08.01.08.005---
Therapeutic response unexpected08.06.01.0010.000404%-
Throat irritation07.05.05.037; 22.12.03.0290.000937%-
Tinnitus04.04.01.002; 17.04.07.004--
Transient ischaemic attack17.08.04.001; 24.04.06.0050.000276%
Urethral disorder20.07.01.002---
Urinary incontinence17.05.01.008; 20.02.02.010--
Urinary tract disorder20.08.01.001---
Urinary tract infection11.01.14.004; 20.08.02.001--
Uveitis06.04.03.003; 10.02.01.023--
Vertigo04.04.01.003; 17.02.12.002--
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages